NTRK3 is altered in 3.03% of malignant solid tumor patients [3].

NTRK3 is an inclusion criterion in 26 clinical trials for malignant solid tumor, of which 20 are open and 6 are closed. Of the trials that contain NTRK3 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (1 open), 7 are phase 1/phase 2 (6 open), and 13 are phase 2 (13 open) [4].

Entrectinib and larotrectinib have evidence of efficacy in patients with NTRK3 mutation in malignant solid tumor [4].

NTRK3 is altered in 5.73% of non-small cell lung carcinoma patients [3].

NTRK3 is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain NTRK3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 7 are phase 2 (7 open) [4].

NTRK3 is an inclusion criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain NTRK3 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [4].

NTRK3 is an inclusion criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain NTRK3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [4].

NTRK3 is altered in 10.13% of melanoma patients [3].

NTRK3 is an inclusion criterion in 3 clinical trials for melanoma, of which 2 are open and 1 is closed. Of the trials that contain NTRK3 status and melanoma as inclusion criteria, 3 are phase 2 (2 open) [4].

NTRK3 is altered in 3.77% of colorectal carcinoma patients [3].

NTRK3 is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NTRK3 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

NTRK3 is altered in 1.41% of breast carcinoma patients [3].

NTRK3 is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NTRK3 status and breast carcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].

NTRK3 is altered in 0.26% of acute myeloid leukemia patients [3].

NTRK3 is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain NTRK3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

NTRK3 is an inclusion criterion in 3 clinical trials for congenital mesoblastic nephroma, of which 3 are open and 0 are closed. Of the trials that contain NTRK3 status and congenital mesoblastic nephroma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

NTRK3 is an inclusion criterion in 3 clinical trials for infantile fibrosarcoma, of which 3 are open and 0 are closed. Of the trials that contain NTRK3 status and infantile fibrosarcoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

NTRK3 is altered in 5.69% of lung carcinoma patients [3].

NTRK3 is an inclusion criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

NTRK3 is altered in 2.72% of head and neck squamous cell carcinoma patients [3].

NTRK3 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

NTRK3 is altered in 0.95% of multiple myeloma patients [3].

NTRK3 is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [4].

NTRK3 is altered in 0.66% of lymphoma patients [3].

NTRK3 is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain NTRK3 status and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].

NTRK3 is altered in 0.66% of non-hodgkin lymphoma patients [3].

NTRK3 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

NTRK3 is altered in 0.15% of myelodysplastic syndromes patients [3].

NTRK3 is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [4].

NTRK3 is an inclusion criterion in 2 clinical trials for anaplastic large cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

NTRK3 is an inclusion criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [4].

NTRK3 is altered in 100.0% of secretory breast carcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for secretory breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and secretory breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NTRK3 is altered in 5.94% of squamous cell lung carcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 5.59% of lung adenocarcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 3.77% of malignant colorectal neoplasm patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for malignant colorectal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and malignant colorectal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 3.3% of gastric adenocarcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 3.0% of bladder carcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 3.06% of malignant uterine neoplasm patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 3.13% of adenocarcinoma of the gastroesophageal junction patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 3.26% of head and neck carcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 2.6% of ovarian carcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 2.48% of malignant ovarian neoplasm patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for malignant ovarian neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and malignant ovarian neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 1.67% of esophageal squamous cell carcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 1.88% of bile duct carcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 1.59% of gallbladder carcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 1.47% of cervical carcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 1.49% of malignant glioma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [4].

NTRK3 is altered in 2.01% of soft tissue sarcoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 1.18% of central nervous system neoplasm patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NTRK3 is altered in 1.08% of pancreatic carcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 0.79% of histiocytic and dendritic cell neoplasm patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 0.78% of kidney carcinoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for kidney carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and kidney carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 0.61% of B-cell non-hodgkin lymphoma patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is altered in 0.25% of acute leukemia patients [3].

NTRK3 is an inclusion criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

NTRK3 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].